Peptipedia
Weight LossNot FDA ApprovedClinical Trials

Orforglipron

Also known as LY3502970, OWL833

An oral non-peptide GLP-1 receptor agonist. First oral GLP-1 agonist not requiring food restrictions.

NDA Under Review - FDA decision expected April 10, 2026
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

12-45 mg once daily

Frequency

Once daily

Duration

Long-term use expected

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 12-45 mg once daily via Oral tablet daily, Once daily. Dose range: 12-45 mg daily. Duration: Long-term use expected.

Timing & Administration

Administer via Oral tablet daily. Frequency: Once daily.

Mechanism of Action

Activates GLP-1 receptors similarly to peptide GLP-1 agonists with oral bioavailability advantages.

Research Summary

Evidence level: clinical trials. Clinical status: NDA Under Review - FDA decision expected April 10, 2026.

Side Effects & Safety

Important Warnings

  • NDA under FDA review; not yet approved
Diarrhea (19-26%)
nausea (13-18%)
vomiting
mild-to-moderate GI events
pulse increase

References

No references available.

Related Peptides

Browse all →
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile
TirzepatideWeight Loss

A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.

View profile
RetatrutideWeight Loss

A triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.

View profile